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Background. Mesenchymal stem cells (MSCs) have a therapeutic potential for the treatment of osteoarthritic (OA) joint pathology
and pain. The aims of this study were to determine the inﬂuence of a passage number on the eﬀects of MSCs on pain behaviour and
cartilage and bone features in a rodent model of OA.Methods. Rats underwent either medial meniscal transection (MNX) or sham
surgery under anaesthesia. Rats received intra-articular injection of either 1.5× 106 late passage MSCs labelled with 10μg/ml
SiMAG, 1.5× 106 late passage mesenchymal stem cells, the steroid Kenalog (200 μg/20 μL), 1.5× 106 early passage MSCs, or
serum-free media (SFM). Sham-operated rats received intra-articular injection of SFM. Pain behaviour was quantiﬁed until day
42 postmodel induction. Magnetic resonance imaging (MRI) was used to localise the labelled cells within the knee joint. Results.
Late passage MSCs and Kenalog attenuated established pain behaviour in MNX rats, but did not alter MNX-induced joint
pathology at the end of the study period. Early passage MSCs exacerbated MNX-induced pain behaviour for up to one week
postinjection and did not alter joint pathology. Conclusion. Our data demonstrate for the ﬁrst time the role of a passage number
in inﬂuencing the therapeutic eﬀects of MSCs in a model of OA pain.
1. Introduction
Osteoarthritis (OA) is the most common joint disease in
adults, and current prevalence is 12% in the population> 60
years,whichwill escalateover thenext20years [1, 2].Although
there is controversy in the ﬁeld, it is acknowledged that a
broad spectrum of proinﬂammatory pathways and cata-
bolic factors contributes to the initiation of OA, which
impacts upon both the joint cartilage, synovium, and bone [1].
Pain is one of the ﬁrst symptoms of knee OA; it can progress
to be continuous, reducing movement and quality of life [1].
The mechanisms underlying OA pain involve structural
changes and alterations in peripheral transduction and cen-
tral processing of painful sensory inputs. Current treatments
for OA pain have limited eﬃcacy [3], and total joint replace-
ment (TJR) surgery is a common outcome [1]. TJR surgery
often reverses central sensitization, indicating that nocicep-
tive output from the joint is fundamental in driving central
pain mechanisms [4]. However, surgery is not suitable for
patients< 55 years [5], and it remains critical that numbers
of people with OA pain reliant on joint replacement as a
treatment are reduced.
An alternative approach is the development of more
eﬀective cell-based therapies that limit the joint pathology
and reduce synovial inﬂammation, which is signiﬁcantly
associated with OA pain [6].
Mesenchymal stem cells (MSCs) have a potential as a
therapy for OA [7–10]. MSCs readily diﬀerentiate into bone,
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cartilage, and adipose cells and release soluble factors (such
as growth factors and chemokines) which harbour a regener-
ative environment through a variety of mechanisms [9, 11].
Animal models mimicking pathological and pain compo-
nents of OA are widely used [12–14]; intra-articular injection
of rat bone marrow-derived MSCs reduced pain behaviour
in the absence of an eﬀect on joint pathology in the mono-
sodium iodoacetate model of OA in the rat [15] and had
signiﬁcant chondroprotective and anti-inﬂammatory eﬀects
in a rat surgical model of OA, but pain was not assessed
[16]. Similarly, local delivery of adult MSCs was associated
with regeneration of meniscal tissue and reduced joint
destruction in a caprine model of OA [17]. Increased pas-
sage number from 4 to 9 of human adipose-derived adult
stem cells increases the chondrogenic potential of cells
[18]; whether this translates into improved beneﬁt in vivo
has yet to be addressed.
Maximising the therapeutic potential of cell-based
therapies for the treatment of OA pain requires further
understanding of the conditions required to maximise the
potential therapeutic eﬀect of MSCs, and knowledge of their
sites and mechanisms of action, which requires monitoring
of implanted cells within the joint. The aim of the present
study was to compare eﬀects of early versus late passage
MSCs on pain behaviour, structural changes to the knee
joint, and circulating levels of tumor necrosis factor alpha
(TNFα) and interleukin 10 (IL-10) in a surgical model of
OA in the rat. Tracking and imaging of the MSCs within
the joint were achieved using magnetic resonance imaging
(MRI) of superparamagnetic iron oxide nanoparticles
(SPION) internalised by MSCs in a subset of the groups
within the study.
2. Materials and Methods
2.1. Cell Isolation, Expansion, and Characterisation. Early
passage bone marrow murine MSCs (P3) were isolated from
Balb/c mice, and late passage cells (P9) were isolated from
C57Bl/6 mice as previously described [19]. Both sets of cells
were fully characterised for membrane receptor expression
of CD31, CD44, CD11b, CD45, CD105, and Ly-6A(Sca-
1)PE, three lineage diﬀerentiation, and colony-forming unit
ﬁbroblast assay (CFU-F) (see Supplementary Information).
2.2. Magnetic Nanoparticle (MNPs) Labelling. MSCs were
labelled with SiMAG (1000 nm; particle size) (Chemicell,
Germany). These are commercially available MNPs consist-
ing of a maghemite iron oxide core (Fe2O3) and an unmodi-
ﬁed silica surface with terminal negatively charged silanol
groups. Cell were labelled using a passive incubation method
as described by Markides et al. [20]. In brief, MNPs were
suspended in serum-free CIM (cell isolation media) and
added directly to cells in culture. Following a 24-hour incu-
bation period, cells were washed three times with phosphate
buﬀered saline (PBS) to remove noninternalised MNPs.
2.3. CellTracker™ CM-DiI Fluorescent Dye Labelling. A
1mg/ml stock solution of the red ﬂuorescent CellTracker
CM-DiI (Molecular Probes, UK) was prepared in dimethyl
sulfoxide (DMSO). MSCs were trypsinized, washed with
PBS, and incubated with CM-DiI (2.5μl of stock per 1ml of
PBS) for 5 minutes at 37°C, and then for an additional 15
minutes at 4°C, in darkness.
Unincorporated dye was then removed by centrifugation
at 300g for 5 minutes and 2 washes in PBS. Cells were resus-
pended in serum-free IMDM (Iscove’s Modiﬁed Dulbecco’s
Medium) and maintained at 4° until injection.
2.4. MSC-Conditioned Medium Studies. Cells used for con-
ditioned medium studies were previously isolated from
C57Bl/6 and Balb/c mice and expanded in vitro. For testing,
conditioned medium was prepared using murine bone
marrow-derived MSC at P3 and P10. Conditioned medium
was prepared using serum-free IMDM (SF-IMDM) (GIBCO,
Life Technologies) with no supplements added as described
previously [21]. Brieﬂy, cells were expanded to conﬂuence
using cell expansion medium (CEM, comprising IMDMwith
9% FBS, 9% Horse Serum, and 1% Pen/Strep). Flasks were
then rinsed three times with DPBS and once with SF-
IMDM before adding 12ml SF-IMDM. Following this, ﬂasks
were incubated at 37°C, 5% CO2 with SF-IMDMwithout cells
used for controls. After 48-hour incubation, the medium was
removed and centrifuged for 5 minutes at 1200g to remove
cell debris. 11ml supernatant was then passed through
3 kDa centrifugal ﬁlters (amicon ultra 15 centrifugal ﬁlter
tubes, Merck Millipore, Hertfordshire, UK) at 4000g for 40
minutes at 4°C, and residual supernatant was removed from
ﬁlters and immediately frozen to −80°C until testing.
2.5. Rat Model of Osteoarthritis Pain. Male Sprague Dawley
rats (weighing 160–190 g) were purchased from Charles
River UK. Studies were carried out in accordance with UK
Home Oﬃce Animals (Scientiﬁc Procedures) Act (1986)
and the guidelines of the International Association for the
Study of Pain. Further, all works were conducted under
Home Oﬃce project licence number 40-3647. Studies were
undertaken in a blinded fashion. Rats underwent medial
meniscal transection (MNX), or sham surgery, as previously
described [22]. The surgical MNX model of OA in rats has
been demonstrated to induce symptoms comparable to that
seen in human OA for pain behaviour, weight-bearing
asymmetry, and disease pathology, through synovitis,
pathology of the subchondral bone, and chondropathology,
as well as the development of osteophytes [13, 22–24]. Rats
were anaesthetised with isoﬂurane (3% induction, 2–2.5%
maintenance; 1 L/min O2), and local anaesthetic EMLA
cream was applied to the left hind limb. A full thickness
cut through the medial meniscus of the left knee was
performed. Sham-operated rats had their meniscus exposed,
but not transected. Recovery from anaesthesia was moni-
tored, and weight gain and general behaviour were moni-
tored throughout the postinjury period.
2.6. Intervention Studies and Pain Behaviour. Baseline mea-
surements were taken prior to surgery (day 0) and from
day 3 onwards. Behavioural assessment of changes in weight
distribution and sensitivity to mechanical stimuli applied to
the hindpaw were performed for up to 42 days postsurgery
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(see Supplementary Information). Two separate intervention
studies were undertaken at 14 days postsurgery (MNX and
sham). Prior to treatment, rats were stratiﬁed according to
weight bearing and paw withdrawal thresholds (PWTs)
(days 3–14) to ensure balanced groups. Under brief isoﬂur-
ane anaesthesia (3% 1L/min O2), rats received one intra-
articular injection.
2.6.1. Study 1: Late Passage MSCs (P.10). MNX rats received
intra-articular injection of either 1.5× 106 mesenchymal stem
cells labelled with 10μg/ml SiMAG (MSC-MNP; n = 11 rats),
1.5× 106 mesenchymal stem cells (MSC-VEH; n = 12 rats), or
serum-free media (SFM; n = 12 rats). Sham-operated rats
received intra-articular injection of serum-free media (SFM;
n = 8 rats).
2.6.2. Study 2: Early Passage MSCs (P.3) versus Steroid
Treatment. MNX rats received intra-articular injection of
200μg/20μL Kenalog (n = 8), 1.5× 106 MSC (n = 10 rats),
or serum-free media (n = 10 rats). Sham-operated rats
received serum-free media (SFM; n = 8 rats).
Following intra-articular injection, rats recovered from
anaesthesia and were returned to the home cage. Weight
bearing and PWTs were assessed on days 21, 28, 31, 35,
and 38 post sham/MNX surgery. Experiments were termi-
nated on day 42.
2.7. Magnetic Resonance Imaging (MRI). The in vivoMRI vis-
ibility threshold was determined previously by intra-articular
injection of either 1× 106 or 2× 106 MSCs labeled with 0, 1, 5,
and 10μg/ml SiMAG into the joint of nonarthritic cadaveric
18-week-old Wistar rats. Rats were MR imaged using a
Brucker 2.3 T animal scanner with the following sequence
parameters; T2-weighted GEFI sequences, TR=700ms,
TE=5.5ms, Flip angle = 30° and FoV=7.9× 7.9 cm, and
matrix size = 256× 192 to determine the location of the
MNPs. MR images and signal loss proﬁles were compared
to the untreated control groups and also between the treat-
ment groups. Study 1 rats were sacriﬁced on day 42 and
immediately MR imaged using the same system described
above. Signal loss proﬁles were obtained and compared
across all the groups. For details on data analysis, see
Supplementary Information.
2.8. Histology. At sacriﬁce, tibiofemoral joints were removed
and postﬁxed in neutral buﬀered formalin (4% formalde-
hyde) decalciﬁed in ethylenediaminetetraacetic acid (EDTA)
[24]. Histomorphometry was performed by an observer
blinded to treatment. Coronal tissue sections (Osteoarthritis
Research Society International (OARSI) guideline for histo-
logical assessment for OA in the rat) were cut at 5μm [25].
Haematoxylin and eosin (H&E) stained sections were
scored for joint morphology [26]. To validate the MRI results
from study 1, midsagittal serial sections (4μm) were obtained
and stained with H&E and the ﬂuorescent dye DAPI (1 : 200
dilution prepared in PBS) in order to visualise implanted
CM-DiI-labelled MSCs (see Supplementary Information).
2.9. ELISA. At sacriﬁce, blood was taken via cardiac punc-
ture, aliquots spun for 20 minutes at 1000g, and serum
supernatant was collected. Serum samples were diluted
2-fold, TNFα using 75μl with calibrator diluent (R&D Sys-
tems, RD5-17), IL-10 using 50μl with assay diluent (R&D
Systems, RD1-21), and βNGF using assay diluent made up
using 10% heat inactivated FBS (Life Technologies Ltd.,
10500-064). Serum levels of TNFα and IL- 10 were deter-
mined using commercially available Enzyme-linked immu-
nosorbant assay (ELISA) kits (RnD Systems, Minneapolis
MN) as per manufacturer’s instructions. Each serum sample
was repeat tested n = 2, and absorption read at 450nm with
correction at 540nm applied. Proprietary kits for measure-
ment of βNGF in rat serum were not available, so compo-
nents were sourced individually with the basic application
using Duoset ELISA Development Kit (R&D Systems
Europe, Ltd., DY556) and recommended components as
per kit instructions (all R&D Systems Europe Ltd.) except
for DPBS (GIBCO, Life Technologies, 14190-169).
2.10. Statistics. Data were analysed using GraphPad Prism
5.0. All data were tested for normality and for nonparametric
testing; Kruskall-Wallis one way ANOVA with Dunn’s post
hoc testing or 2-way ANOVA with Tukey’s post hoc testing
was applied where appropriate, with probability values con-
sidered signiﬁcant at ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001.
3. Results and Discussion Results
3.1. MSC Selection and Characterisation.Murine MSCs were
freshly isolated and expanded in vitro to passage 3 (early pas-
sage) or passage 10 (late passage) with passaging taking place
at 80–90% conﬂuence. Stem cell properties were conﬁrmed
with ﬂow cytometry for a panel of recognised MSC markers
(CD105+, Sca-1+, CD31−, CD11b−, CD45−, CD44+, and
CD34−) (Supplementary Information Figure 1) and selected
for use. Cells were successfully diﬀerentiated towards adipo-
genic, osteogenic, and chondrogenic lineages after 21 days in
culture with relevant diﬀerentiation media (Supplementary
Information Figure 2). CFU-F assay was used to assess the
proliferative capacity of the cells being expanded in culture,
and the results showed that late passage cells retained a high
proliferation rate in culture (early passage 49± 18% versus
late passage 51.5± 12%). Early and late passage cells were
cultured for conditioned medium collection, and levels of
key cytokines (IL-10, TNFα, and βNGF) were measured
(Supplementary Information Figure 3). Levels of IL-10 in
the conditioned medium were minimal and did not vary
between early and late passage cells. Levels of βNGF were
signiﬁcantly higher in conditioned medium from late
passage MSC, compared to early passage MSC (Student’s
t-test, p < 0 05, n = 6). TNFα was not detected in the con-
ditioned medium under either condition (Supplementary
Information Figure 3).
3.2. MRI of MSCs Labelled with SiMAG In Vivo. The presence
of iron oxide MNPs was detected as a decrease in signal
intensity when MR imaged using T2-weighted MRI
sequences. This signal loss is portrayed visually as black areas
on grey scale MR images, referred to as hypointense regions.
The optimal cell number and SiMAG ratio to ensure good
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MRI visibility over a prolonged period of time were deter-
mined to be 1.5× 106 cells labelled with 10μg/ml of SiMAG
(Supplementary Information Figure 4). This labelling combi-
nation allows for improved visibility thresholds over 1× 106
whilst minimising excessive blooming as seen with 2× 106
cells and was taken forward for subsequent in vivo MRI
tracking studies.
3.3. Eﬀects of MSC Treatment versus Steroid on Pain
Behaviour in a Model of OA. Both sham surgery and MNX
surgery resulted in early changes in weight bearing on the
operated hindlimb. By day 14 postsurgery, there was a clear
diﬀerence between the extent of weight-bearing asymmetry
between the sham and MNX groups, indicative of pain
behaviour in the MNX group. At days 28–38, weight-
bearing asymmetry remained signiﬁcantly increased in the
MNX group, but had returned to baseline in the sham group
(Figure 1(a)). Area under the curve analysis of the last three
timepoints tested (days 31–38) revealed a signiﬁcantly
greater weight-bearing asymmetry in the MNX group com-
pared to the sham control group. Consistent with the studies
in our group, hindpaw withdrawal thresholds (PWTs) were
lowered in both sham and MNX rats following surgery
(Figure 1(c)). There were no signiﬁcant diﬀerences in the
PWTs between the two groups of rats (Figure 1(d)).
The eﬀect of intra-articular injection of 1.5× 106 of late
passage MSCs on established pain behaviour in the MNX
model was determined. MSC treatment did not alter
weight-bearing asymmetry in the week (days 14–21) imme-
diately following treatment (data not shown). By contrast,
there was a signiﬁcant reduction in weight-bearing asymme-
try at later timepoints (days 31, 35, and 38) in the MNX
group treated with late passage MSCs (Figure 2(a)). PWTs
were not altered by the intra-articular injection of late
passage MSCs (Figure 2(b)). The eﬀects of intra-articular
injection of early passage MSCs versus a steroid treatment
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Figure 1: MNX surgery for induction of OA pain, or sham surgery, was performed on day 0. (a) MNX rats receiving SFM exhibited
signiﬁcant diﬀerences in weight-bearing asymmetry, compared to the sham-SFM rats. (b) Area under the curve (AUC) data calculated
for days 31, 35, and 38 postsurgery revealed signiﬁcant weight-bearing asymmetry in MNX rats at the later timepoints of the model. (c)
Paw withdrawal thresholds were not signiﬁcantly diﬀerent in MNX rats, compared to sham controls at individual timepoints, or following
AUC analysis. (d) Statistical comparison of the groups at each timepoint: two-way ANOVA with Bonferroni’s post hoc. Comparison of
AUC used a Mann–Whitney’s nonparametric unpaired t-test. ∗p < 0 05, ∗∗p < 0 01 MNX versus sham. Data are mean± SEM, n= 8–10
per group.
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on pain behaviour in the MNX model were determined in
separate groups of rats. Intra-articular injection of early
passage MSC at day 14 resulted in a robust and signiﬁcant
increase in weight-bearing asymmetry at days 17 and 21 post
model induction (Figure 3(a)). At later timepoints (days
29–38), weight-bearing asymmetry was comparable between
the MNX-MSC group and the MNX-SFM group (Figure 3).
Intra-articular injection of the steroid Kenalog at day 14
in MNX rats resulted in a complete reversal of weight-
bearing asymmetry at days 17 and 21 (Figure 3). At later
timepoints (days 29–38), Kenalog ceased to inhibit weight-
bearing asymmetry and there were no diﬀerences between
the MNX-SFM control group and the MNX Kenalog treat-
ment group (Figure 3(b)).
3.4. Joint Pathology, Inﬂammation, and Pain-Related
Cytokines. Analysis of joint histology at the end of the study
revealed that MNX surgery resulted in a signiﬁcant chon-
dropathy score (Figure 4(a)), inﬂammation score of the
synovium (Figure 4(b)), and an increase in the number of
osteophytes (Figure 4(c)). At this ﬁnal timepoint, none of
the treatments signiﬁcantly altered joint chondropathy or
inﬂammation (Figures 4(a), 4(b), and 4(c)). Serum levels
of three cytokines were measured in the diﬀerent treatment
groups at the end of the study (day 42 postsurgery). There
were no diﬀerences in IL-10 expression between the treat-
ment groups (Figure 4(d)). There was a signiﬁcant increase
in serum TNFα in the MNX-MSC early passage treatment
group, compared to the sham-SFM controls and MNX-
MSC late passage treatment group (Figure 4(e)). There were
no signiﬁcant diﬀerences in serum βNGF expression between
the groups (Figure 4(f)).
3.5. MRI Tracking. A subset of rats received intra-articular
injection of SiMAG-labelled MSCs (MSC-MNP) for terminal
MRI imaging at 29 days post cell implantation. MRI revealed
regions of increased hypointensity (black areas) localised
to the synovial cavity of rats treated with MSC-MNP
(Figure 5). In contrast, no hypointense regions were evident
in the groups treated with MSCs (MSC-VEH) or serum-
free media (SFM). To further validate these data, signal loss
proﬁles were plotted for the diﬀerent treatment groups and
revealed a signiﬁcant signal loss in the MSC-MNP group,
compared to unlabelled MSCs (MSC-VEH) and SFM which
had a relatively high signal intensity across the joint
(Figure 5). In a subset of rats, it was conﬁrmed that there
were no diﬀerences between the eﬀects of SiMAG-labelled
MSCs and unlabelled MSCs on pain behaviour (data not
shown). H&E staining was used to identify key structural
features of the knee joint whilst identifying the location of
the ﬂuorescently labelled MSCs. CM-DiI-labelled MSCs
were identiﬁed in the synovium of all MSC-treated groups
(MSC-MNP and MSC-VEH) but not in the SFM-treated
group (Figure 5).
4. Discussion
This study presents new evidence that passage number of
MSCs markedly inﬂuences the eﬀects of these cells on pain
behaviour following their injection into the knee joint in a
surgical model of OA pain. We report that late passage
MSCs signiﬁcantly reduced weight-bearing diﬀerence, a sur-
rogate index of pain on loading, whereas early passage MSCs
exacerbated weight-bearing diﬀerence for a period of 7 days
postinjection in the MNX model. Despite the beneﬁcial
eﬀects of the late passage MSCs on pain behaviour in the
MNX model, there was no evidence for an alteration in the
progression of joint pathology or inﬂammation at the end
of the study. Nevertheless, a peripheral site of action of the
MSCs was supported by the demonstration that SiMAG-
labelled MSCs were detected within the synovial cavity at
29 days postinjection.
As joint degeneration progresses, a variety of surgical
procedures can rebuild the degenerated cartilage lesions,
but do not necessarily reduce the generalised joint inﬂam-
matory processes. Chondrocytes as a cell-based therapy
(autologous chondrocyte implantation (ACI)) were success-
fully developed and used widely over the past 10 years, but
⁎250
200
150
100
50
0
MNX-SFM MNX-mMSC
%
 m
ea
n 
M
N
X 
W
B
(a)
%
 m
ea
n 
M
N
X 
PW
T
250
200
150
100
50
0
MNX-SFM MNX-mMSC
(b)
Figure 2: Rats received an intra-articular injection of 1.5× 106 late passage mouse mesenchymal stem cells (mMSCs) from the bone marrow
of Balb/c mice in 50μL serum-free medium (SFM) or 50 μL SFM (vehicle) on day 14 post MNX surgery. (a) Intra-articular injection of MSCs
signiﬁcantly altered MNX-induced changes in the weight-bearing asymmetry. (b) Paw withdrawal thresholds in MNX rats were unaltered by
the treatment. Data are expressed as a % of the mean MNX-SFM AUC for three timepoints (31, 35, and 38 days) postsurgery. Statistical
analysis used a Mann–Whitney nonparametric unpaired t-test. Data are mean± SEM, MNX-SFM (n = 11), MNX-MSC (n = 22). WB:
weight-bearing asymmetry; PWT: paw withdrawal thresholds. ∗p < 0 05 MNX-MSC versus MNX-SFM.
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this treatment relies on damaging healthy cartilage to pro-
vide the cell sources. The therapeutic potential of alternate
sources of cells, such as MSCs derived from the bone
marrow, which have anti-inﬂammatory and immunosup-
pressive properties, has been investigated. Our ﬁnding that
late passage MSCs attenuated established weight-bearing
asymmetry in the MNX model is consistent with the report
that intra-articular injection of MSCs reversed pain behav-
iour compared to pretreatment values, but did not alter
structural damage or synovial inﬂammation in the chemical
monosodium iodoacetate model of OA pain [27]. The
clinical validity of animal models of OA continues to be
debated, both in terms of the aetiology of the joint damage
and the temporal progression of the structural changes seen
in these models, compared to disease progression in
patients. The MNX model of OA is believed to replicate
some of the key biomechanical events that lead to clinical
joint pathology, as well as displaying many of the features
associated with joint pathology in OA (see refs in [28]).
Our evidence that intra-articular injection of early passage
MSCs exacerbated pain behaviour in the model of OA pro-
vides important new knowledge of the conditions under
which the therapeutic potential of MSCs for OA pain can
be harnessed.
Our data were built upon the previous studies that
focused on the potential for MSCs to mediate joint repair.
Indeed, therapeutic beneﬁt of intra-articular injection of
autologous MSCs has been reported in a surgical model of
OA in the goat [17], and more recent studies report beneﬁcial
eﬀects of MSCs from bone marrow and adipose in models of
OA and extend the initial evidence by demonstrating repara-
tive eﬀects of the cells on the cartilage [29, 30]. The progres-
sion of MNX-induced joint pathology was not halted by
intra-articular injection of late passage MSCs, suggesting that
at least in this model the eﬀects of MSC treatment on pain
behaviour are not associated with increased joint repair.
Despite this lack of eﬀect on joint pathology, our study did
provide evidence for changes in systemic inﬂammation.
There was a trend towards an increase in serum TNFα in
the MNX model of OA pain, compared to the sham control
group at day 42 postsurgery. Interestingly, MNX rats treated
with the early passage MSCs had signiﬁcantly increased
serum TNFα, compared to the sham group, consistent with
the exacerbation of pain behaviour by this treatment. By con-
trast, serum TNFα was signiﬁcantly lower in MNX rats
treated with late passage MSCs, compared to early passage
MSCs. These data are consistent with the ability of late pas-
sage, but not early passage, MSCs to reduce pain behaviour.
Pharmacological studies using comparable methods demon-
strated a signiﬁcant increase in plasma TNFα in the MIA
model of OA pain compared to control rats, with these
changes reversed by an analgesic treatment [31]. Although
both IL-10 and NGF were detected in the serum, there were
no signiﬁcant diﬀerences between the treatment groups, sug-
gesting that changes in TNFα do not reﬂect a generalised
change in inﬂammation.
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Figure 3: (a) Timecourse of the eﬀects of intra-articular injection of the steroid Kenalog (200 μg/20μL) versus 1.5× 106 of early passage
mMSC on weight-bearing asymmetry. Rats received the active treatments or 50μL SFM (vehicle) on day 14 postsurgery. Kenalog had a
rapid inhibitory eﬀect on MNX-induced weight-bearing asymmetry at 17 and 21 days post model induction, compared to the MNX-SFM
group. mMSC treatment signiﬁcantly increased weight-bearing asymmetry at early timepoints (days 17 and 21) post model induction. At
later timepoints, weight-bearing asymmetry was comparable between the MNX-MSC group and the MNX-SFM group. Data was analysed
using a 2-way ANOVA with Tukey’s post hoc test. ∗∗p < 0 01 MNX-SFM versus sham-SFM, ##p < 0 01 MNX-MSC versus MNX-SFM;
@p < 0 05, @@@@p < 0 0001 MNX steroid versus MNX-MSC. (b) Area under the curve (AUC) analysis of the eﬀects of intra-articular
injection of steroid Kenalog versus 1.5× 106 of early passage mMSC on MNX-induced weight-bearing asymmetry for the last three
timepoints (days 31, 35, and 38). mMSC treatment did not alter weight-bearing asymmetry in MNX rats. Although there was a trend
towards an inhibition of weight-bearing asymmetry by Kenalog, this was only signiﬁcantly compared to the MNX-mMSC group.
Data are expressed as a % of the mean MNX-SFM AUC for timepoints 31, 35, and 38 days postsurgery. Statistical analysis used a
Kruskal-Wallis test with Dunn’s post hoc, ∗p < 0 05. Data are mean± SEM, n= 9-10 per group.
6 Stem Cells International
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
Chondropathy
15
10
5
0
Ch
on
dr
op
at
hy
 (i
nv
ol
vm
en
t⁎
da
m
ag
e)
Sh
am
-S
FM
M
N
X-
SF
M
N
X-
M
SC
ea
rly
 p
as
sa
ge
M
N
X-
Ke
na
lo
g
M
N
X-
M
SC
la
te
 p
as
sa
ge
⁎⁎
(a)
In
fla
m
m
at
io
n 
sc
or
e
Inflammation
3
2
1
0
Sh
am
-S
FM
M
N
X-
SF
M
N
X-
M
SC
ea
rly
 p
as
sa
ge
M
N
X-
Ke
na
lo
g
M
N
X-
M
SC
la
te
 p
as
sa
ge
⁎⁎⁎ ⁎⁎⁎ ⁎⁎⁎
⁎⁎
(b)
O
ste
op
hy
te
 sc
or
e
Osteophytes
3
2
1
0
Sh
am
-S
FM
M
N
X-
SF
M
N
X-
M
SC
ea
rly
 p
as
sa
ge
M
N
X-
Ke
na
lo
g
M
N
X-
M
SC
 
la
te
 p
as
sa
ge
⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎ ⁎⁎⁎
(c)
IL-10
7
6
5
4
3
2
1
0
D
et
ec
tio
n 
(p
m
ol
/g
)
Sh
am
-S
FM
M
N
X-
SF
M
N
X-
M
SC
ea
rly
 p
as
sa
ge
M
N
X-
Ke
na
lo
g
M
N
X-
M
SC
la
te
 p
as
sa
ge
(d)
TNF훼
4
3
2
1
0
D
et
ec
tio
n 
(p
m
ol
/g
)
Sh
am
-S
FM
M
N
X-
SF
M
N
X-
M
SC
ea
rly
 p
as
sa
ge
M
N
X-
Ke
na
lo
g
M
N
X-
M
SC
la
te
 p
as
sa
ge
⁎ ⁎
(e)
훽NGF
90
80
70
60
50
40
30
20
10
0
D
et
ec
tio
n 
(p
m
ol
/g
)
Sh
am
-S
FM
M
N
X-
SF
M
N
X-
M
SC
ea
rly
 p
as
sa
ge
M
N
X-
Ke
na
lo
g
M
N
X-
M
SC
 
la
te
 p
as
sa
ge
(f)
Figure 4: (a–c) MNX surgery was associated with signiﬁcant chondropathy (a), joint inﬂammation (b), and increased presence of osteophytes
(c), compared to sham controls at 42 days postsurgery. None of the treatments in MNX rats signiﬁcantly altered the extent of chondropathy,
inﬂammation, or osteophyte number. Statistical analysis used Kruskal-Wallis test with Dunn’s post hoc, ∗∗p < 0 01, ∗∗∗p < 0 001. Data are
mean± SEM, 2–4 sections per rats were analysed, and total numbers of sections are sham-SFM: 37; MNX-SFM: 55; MNX-MSC early
passage: 44; MNX Kenalog: 42; MNX-MSC late passage: 20. (d–f) Serum levels of cytokines in MNX- and sham-operated rats at 42 days
postsurgery. There were no diﬀerences in IL-10 expression between the treatment groups (d). There was a signiﬁcant increase in serum
TNFα in the MNX-MSC early passage treatment group, compared to the sham-SFM controls and MNX-MSC late passage treatment
group (e). There were no signiﬁcant diﬀerences in serum βNGF expression between the groups. Statistical analysis used Kruskal-Wallis
test with Dunn’s post hoc, ∗p < 0 05, ∗∗∗p < 0 001. Data are overall mean± SEM, whilst mean values from duplicate samples per rat were
analysed; total numbers of mean values are sham-SFM: 15; MNX-SFM: 22; MNX-MSC early passage: 10; MNX Kenalog: 9; and MNX-
MSC late passage: 23.
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Understanding the diﬀerences in properties of the early
versus late passage MSCs that lead to the behavioural out-
comes will help reﬁne MSC treatment strategies. Prolonged
in vitro culture of bone marrow-derived MSCs leads to a loss
of MSC phenotype, multipotency, decreased wound homing
properties [32], and self-renewal by around passage 15–20,
associated with the onset of cellular senescence [33–36]. As
a result, the use of early passage cells is recommended; how-
ever, early passage cell populations have increased likelihood
of heterogeneity whilst late passage cells retain characteristic
markers for MSC phenotype in a selectively more homoge-
nous population [36, 37]. The immunomodulatory proper-
ties of MSCs in a long-term culture have been reported.
Late passage MSCs of umbilical origin (passage 15) show
signiﬁcant upregulation of anti-inﬂammatory mediator
HMOX-1, a modulator of IL-10 and NO activity [38, 39];
downregulation of proinﬂammatory IL-1α, IL-1β, and
IFN-γ; reduced proliferation of PHA-stimulated peripheral
blood mononuclear cells, implicated in expression of proin-
ﬂammatory cytokines; and no change in expression of
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Figure 5: (a): Sagittal MRI scans; Location of SiMAG-labelled cells are depicted as areas of hypointense signal loss and highlighted by the red
ring over the synovial cavity. (b) Corresponding histological sections. Fluorescent images correspond to location marked X on H&E images
(inset). Implanted DiI-labelledMSCs are shown in red whilst all native materials are show by DAPI in blue. (c) CorrespondingMRI signal loss
proﬁle. Groups include (i) SiMAG-labelled MSCs (MSC-MNP), (ii) MSCs only (MSC-VEH), and (iii) serum-free media. T: tibia; F: femur; S:
synovial lining; M: meniscus. Scale bars = 100 μm.
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TGF-β, a cytokine critical to the immunosuppressive capa-
bilities of transfused MSC [39]. It may therefore follow in
our study that IFN-γ production is impaired and macro-
phage balance shifts from M1 to M2, as seen previously
with in vivo MSC transplantation [40]. Production of IL-6
is increased in the late passage human bone marrow-
derived MSC compared to early passage cells, whilst
CXCL8 levels fall [41]. IL-6 has both anti- and proinﬂam-
matory activities and may function here to activate IL-10
and bind to toll-like receptors to inhibit proinﬂammatory
cytokine production, for example, TNF-α and IL-1, whilst
also providing protection against bacterial proliferation
[42, 43]. More analyses of the cytokine proﬁle are needed
to deﬁne exact pathways in the variation in potential
immunomodulation between early and late passage MSCs
in our model of OA pain.
There is evidence of other phenotypic shifts in MSCs
with prolonged culture which may provide insight. For
example, prolonged culture of MSCs reduces STRO-1 and
BMP7 expression, changes alkaline phosphatase activity,
and reduces osteogenic capability [36, 44, 45]. Earlier stud-
ies, examining passage-dependent diﬀerences to chondro-
genic potential of MSCs, have produced varied results, with
some studies reporting a maintenance of the chondrogenic
potential of the cells up to passage 20 [46], or increase in
COL2A1 and AGC1 expression from P4 to P9 in human
adipose-derived adult stem [18]. Another study reported a
reduction of chondrogenic capabilities of MSCs at late
passage [33, 35, 47]. With an increasing passage number,
MSC isolated from synovium shows migratory behaviour
similar to chondrocytes, whilst at low passage (p < 4), a
reduced ability to undergo chondrogenesis was observed
[48]. Our results revealed that late passage MSCs attenuated
established pain behaviour (weight-bearing asymmetry) in
MNX rats, but did not alter MNX-induced joint pathology.
This suggests that higher passage cells may have an
increased potential for therapeutic application. What is clear
is that selection of populations of cells for therapy will
depend on the level of preculture with signiﬁcant changes
in phenotype and potential therapeutic activity as a result
of prolonged culture. The trade-oﬀ between eﬃcacy and cell
number generated by scale-up of cell numbers will be an
important consideration in a therapeutic design. Future
studies of earlier experimental timepoints will shed light on
the eﬀects of treatments on the alleviation of pain and mod-
eration of inﬂammatory response following MSC treatment.
The key to enabling the translation of MSC treatment for
OA to the clinic is the tracking of the cells following injection
into the knee joint to initially demonstrate eﬀective delivery
of cells and to monitor cell retention and biodistribution
thereafter. Previously, we have shown that SiMAG, a com-
mercially available superparamagnetic iron oxide nanoparti-
cles (SPIONs), can be used to track the migration of MSCs
over 7 days and localise them to the knee joint in a mouse
model of rheumatoid arthritis (RA) [20]. Importantly, the
same study demonstrated no adverse eﬀects in terms of
in vitro MSC properties, cell viability, and proliferation as a
result of SiMAG labelling. Furthermore, the delivery of
SiMAG-labelled MSCs was also well tolerated by mice
thereby encouraging the use of SiMAG as an imaging and
tracking agent in this current study. Although a number of
noninvasive imaging modalities can be applied to track cells
post implantation, SPION- and MRI-based tracking tech-
niques beneﬁt from relatively long-term and longitudinal
monitoring of implanted cell populations. In a recent study
by van Buul et al. [27], implanted MSC populations were
monitored by bioluminescence and MRI with MSCs trans-
fected with ﬁreﬂy luciferase and labelled with a particular
SPION known as Endorem. A gradual and complete loss in
bioluminescence signal was observed over a 3-week period.
By contrast, the SPION-based component of this system
has the potential to allow SPION-labelled cells to be moni-
tored for up to 12 weeks as demonstrated by 2 independent
studies by Jing et al. [49] and Chen et al. [50]. In these studies,
Endorem-labelled MSCs and chondrocytes were monitored
in vivo for up to 12 weeks within the knee joint [49, 50]. Nev-
ertheless, unlike bioluminescence, the viability of implanted
cells cannot be determined by MRI-based modalities. In our
study, SiMAG-labelled cell was successfully observed up to
29 days post implantation.
5. Conclusions
We have demonstrated diﬀerences in pain responses in a rat
surgical model of OA following cell therapy using popula-
tions of MSCs at early and late passages following isolation
from the bone marrow. Late passage MSCs signiﬁcantly
reduced weight-bearing diﬀerence, a surrogate index of pain
on loading (days 31, 35, and 38), whereas early passage
MSCs exacerbated weight-bearing diﬀerence for a period of
7 days postinjection in the MNX model. Neither treatment
altered progression of joint pathology nor inﬂammation
quantiﬁed at the end of the study. Our data provide further
evidence for the need for characterisation of this cell type
prior to clinical use due to its multifunctional nature and
the changing phenotype from repair to immunomodulation
with time in culture.
Ethical Approval
All studies were approved by local ethics committee. Exper-
iments were carried out in accordance with UK Home
Oﬃce Animals (Scientiﬁc Procedures) Act (1986) and the
guidelines of the International Association for the Study
of Pain.
Conflicts of Interest
The authors declare that there is no conﬂict of interest
regarding the publication of this article.
Acknowledgments
The authors thank the Arthritis Research UK for funding this
work and thank Gemma Turner (Keele University) for the
help with formatting the manuscript. This work was funded
by Arthritis Research UK (Grant nos. 18769 and 19429).
The work was partially funded through the ARUK Centre
9Stem Cells International
for Tissue Engineering and the EPSRC IRC in manufacturing
of regenerative medicine.
Supplementary Materials
Supplementary Figure 1: Cell marker proﬁle for early and
late passage MSC, characterised through CD105+, Sca-1+,
CD31-, CD11b-, CD45-, CD44+, CD34-. CD105 is known
to vary in expression in murine MSC. In this study, cells
at late passage expressed lower levels of CD105 whilst all
other markers were consistently expressed. Supplementary
Figure 2: Tri-lineage diﬀerentiation for early (A) and late
(B) passage cells along adipogenic (1), osteogenic (2) and
chondrogenic (3) lineages. Positive diﬀerentiation was
detected for both early and late passage MSC. Scale bars =
200μm. Supplementary Figure 3: Measurement of cytokines
conditioned media from early and late passage cultured
MSCs. There were no diﬀerences in IL10 levels between the
two conditions. TNFα was not detected in conditioned
medium. Expression of βNGF was signiﬁcantly higher in
late passage MSC compared to early passage MSC (Student’s
t-test, p < 0 05) (n = 6 for all samples). Supplementary
Figure 4: In vivo dose response: Signal loss proﬁles and
corresponding sagittal MR images following the implanta-
tion of (A) 1× 106 and (B) 2× 106 MSCs labelled with (i)
10μg/ml, (ii) 5μg/ml, and (iii) 1μg/ml SiMAG into knee
joints of cadaveric rats and compared to the (iv) untreated
control. Location of SiMAG labelled cells is depicted as areas
of hypointense signal loss and highlighted by the red ring
over the synovial cavity. (Supplementary Materials)
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